Abstract
Background Decision-makers impose COVID-19 mitigations based on public health indicators such as reported cases, which are sensitive to fluctuations in supply and demand for diagnostic testing, and hospital admissions, which lag infections by up to two weeks. Imposing mitigations too early has unnecessary economic costs, while imposing too late leads to uncontrolled epidemics with unnecessary cases and deaths. Sentinel surveillance of recently-symptomatic individuals in outpatient testing sites may overcome biases and lags in conventional indicators, but the minimal outpatient sentinel surveillance system needed for reliable trend estimation remains unknown.
Methods We used a stochastic, compartmental transmission model to evaluate the performance of various surveillance indicators at reliably triggering an alarm in response to, but not before, a step increase in transmission of SARS-CoV-2. The surveillance indicators included hospital admissions, hospital occupancy, and sentinel cases with varying levels of sampling effort capturing 5, 10, 20, 50 or 100% of incident mild cases. We tested 3 levels of transmission increase, 3 population sizes, and condition of either simultaneous transmission increase, or lagged increase in older population. We compared the indicators’ performance at triggering alarm soon after, but not prior, to the transmission increase.
Results Compared to surveillance based on hospital admissions, outpatient sentinel surveillance that captured at least 20% of incident mild cases could trigger alarm 2 to 5 days earlier for a mild increase in transmission and 6 days earlier for moderate or strong increase. Sentinel surveillance triggered fewer false alarms and averted more deaths per day spent in mitigation. When transmission increase in older populations lagged increase in younger populations by 14 days, sentinel surveillance extended its lead time over hospital admissions by an additional 2 days.
Conclusions Sentinel surveillance of mild symptomatic cases can provide more timely and reliable information on changes in transmission to inform decision-makers in an epidemic like COVID-19.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
KBT and JG were supported by the Peter G. Peterson Foundation Pandemic Response Policy Research Fund. MR and JG were supported by the MIDAS rapid response grant (MIDASNI2020-4). RR was supported by a grant from NIGMS (T32 GM008449).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data produced in the present work are contained in the manuscript.
List of abbreviations
- USA
- United States of America
- UK
- United Kingdom
- SEIR
- Susceptible exposed infected recovered
- ICU
- Intensive care unit
- LOWESS
- Locally weighted scatterplot smoothing
- CDC
- Centers for Disease Control and Prevention